Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $32.9 million.

  • IDEAYA Biosciences' Other Accumulated Expenses rose 7280.56% to $32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year increase of 7280.56%. This contributed to the annual value of $20.0 million for FY2024, which is 8692.39% up from last year.
  • As of Q3 2025, IDEAYA Biosciences' Other Accumulated Expenses stood at $32.9 million, which was up 7280.56% from $28.1 million recorded in Q2 2025.
  • IDEAYA Biosciences' Other Accumulated Expenses' 5-year high stood at $32.9 million during Q3 2025, with a 5-year trough of $5.0 million in Q1 2021.
  • In the last 5 years, IDEAYA Biosciences' Other Accumulated Expenses had a median value of $11.2 million in 2022 and averaged $14.0 million.
  • In the last 5 years, IDEAYA Biosciences' Other Accumulated Expenses soared by 17225.73% in 2021 and then plummeted by 2440.5% in 2023.
  • Quarter analysis of 5 years shows IDEAYA Biosciences' Other Accumulated Expenses stood at $7.9 million in 2021, then soared by 41.73% to $11.1 million in 2022, then dropped by 4.22% to $10.7 million in 2023, then surged by 86.92% to $20.0 million in 2024, then soared by 64.75% to $32.9 million in 2025.
  • Its Other Accumulated Expenses was $32.9 million in Q3 2025, compared to $28.1 million in Q2 2025 and $26.0 million in Q1 2025.